Trial Profile
Phase II Study of Everolimus Beyond Progression in Postmenopausal Women With Advanced, Hormone Receptor Positive Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Anastrozole; Fulvestrant; Fulvestrant; Letrozole; Megestrol; Tamoxifen
- Indications Breast cancer
- Focus Therapeutic Use
- 06 Jan 2022 Status changed from active, no longer recruiting to discontinued.
- 24 Jan 2021 Planned primary completion date changed from 1 Nov 2020 to 1 Nov 2021.
- 06 Nov 2019 Planned End Date changed from 1 Oct 2020 to 1 Nov 2021.